Systematic review and meta analysis of randomized controlled trials on Tianmagouteng decoction in treatment of primary hypertension with liver Yang hyperactivity syndrome  by Wu, Xinfang & Jiang, Xiuxin
Online Submissions: http://www.journaltcm.com J Tradit Chin Med 2013 February 15; 33(1): 15-18
info@journaltcm.com ISSN 0255-2922
© 2013 JTCM. All rights reserved.
SYSTEMATIC REVIEW
JTCM |www. journaltcm. com February 15, 2013 |volume 33 | Issue 1 |
Systematic review and meta analysis of randomized controlled tri-
als on Tianmagouteng decoction in treatment of primary hyperten-
sion with liverYang hyperactivity syndrome
XinfangWu, Xiuxin Jiang
aa
Xinfang Wu, South branch of Guang'anmen Hospital, China
Academy of Chinese Medical Sciences, Beijing 102618, China
Xiuxin Jiang, China Academy of Chinese Medical Sciences,
Beijing 100700, China
Correspondence to: Prof. Xinfang Wu, South branch of
Guang'anmen Hospital, China Academy of Chinese Medical
Sciences, Beijing 102618, China.Wuxinfang888@163.com
Telephone: +86-13511026291
Accepted: April 18, 2012
Abstract
OBJECTIVE: To assess the efficacy of Tianma-
gouteng decoction in the treatment of primary hy-
pertension with liver yang hyperactivity syndrome.
METHODS: The databases of MEDLINE (1950-
2012), EMbase (1980-2012), China biology medi-
cine (CBM) (1994-2012), China national knowledge
infrastructure (CNKI) (1989-2012), Weipu (VIP)
(1995-2012) and Wanfang (1989-2012) were
searched and we performed manual searches for
conference proceedings to select randomized con-
trolled trials (RCTs) on Tianmagouteng decoction
for the treatment of primary hypertension with liv-
er Yang hyperactivity syndrome. Studies were en-
rolled according to the study-selecting criteria. The
methodological quality was evaluated, data were
extracted and meta-analyses were conducted with
RevMan 4.2 software.
RESULTS: Nine RCTs were selected involving 784
patients with no significant difference in decrease
in systolic blood pressure (SBP) [OR=1.02, 95% CI
(-0.24, 2.29), P=0.10] and diastolic blood pressure
(DBP) [OR=0.56, 95% CI (-0.10,1.23), P=0.11] be-
tween the Tianmagouteng group and the control
group. While there was a significantly larger in-
crease in serum superoxide dismutase (SOD) [OR=
6.26, 95% CI (1.27,11.66), P=0. 01] in the Tianma-
gouteng group than that in the control group
CONCLUSION: Tianmagouteng decoction can de-
crease both systolic and diastolic blood pressure
and greatly increase serum SOD. Due to poor quali-
ty of included studies, the efficacy needs to be fur-
ther assessed.
© 2013 JTCM. All rights reserved.
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INTRODUCTION
Primary hypertension, a common chronic disease, is a
main risk factor for cardio-cerebro-vascular diseases
and a main cause for stroke and coronary heart disease
in China. At present, because more and more people
are suffering from primary hypertension, long-term,
stable, effective control of blood pressure is the basic
principle for the treatment of primary hypertension.
Tianmagouteng decoction, a formula recorded in Za
Bing Zheng Zhi Xin Yi, is commonly used to treat hy-
pertension. It can calm the liver wind, nourish the liver
and kidney Yin, clear away heat and promote blood cir-
culation,so it has the function of treating liver Yang hy-
peractivity. Currently, there are a lot of studies on the
effect of Tianmagouteng decoction on primary hyper-
tension with liver Yang hyperactivity syndrome. How-
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ever, due to poor methodological quality, the outcome
was not consistent. To get better insight into the effec-
tiveness of Tianmagouteng decoction for treatment of
primary hypertension with liver Yang hyperactivity syn-
drome, we performed a systematic review and me-
ta-analysis of this topic.
METHODS
Literature retrieval
We performed systematic searches for Tianmagouteng
decoction for the treatment of primary hypertension
with liver Yang hyperactivity syndrome in MEDLINE
database (1950-2012), EMbase (1980-2012), Weipu
(VIP) database of Chinese Technical Periodicals
(1995-2012), China biology medicine (CBM)
(1994-2012), China national knowledge infrastructure
(CNKI) (1989-2012) and Wanfangand manual search-
es for conference proceedings by means of the follow-
ing searching terms: 1) Tianmagouteng, 2) liver Yang
hyperactivity, 3) hypertension in several variances and
combinations.
Study selection
The inclusive criteria: 1) randomized controlled trials
(RCTs); 2) The patients in the treatment group receive
Tianmagouteng decoction (or granule), while the pa-
tients in the control group receive Western Medicine;
3) the patients are diagnosed as having primary hyper-
tension with liver Yang hyperactivity syndrome; 4) the
duration is at least 4 weeks. The exclusion criteria: 1)
non-randomized controlled trials; 2) patients in the
treatment group receive other antihypertensive agents
besides Tianmagouteng Yin; 3) the duration is less
than 4 weeks.
Blood pressure (Systolic and Diastolic), Plasma super-
oxide dismutase (SOD), Plasma glutathione peroxidase
(GSH-PX), Plasma malondialdehyde (MDA), Plasma
Nitric Oxide (NO), TCM symptom (Plasma Tradition-
al Chinese Medicine), quality of life and the adverse ef-
fects are measured.
Data extraction and quality assessment
The data extraction and quality assessment of studies
were performed by two independent reviewers,the
methodological quality was assessed according to Jadad
Questionnaire1 and RCTs were assessed with a Jadad
score between zero and five. In assessment of RCTs,
1-2 points was considered as low quality and 3-5
points as high quality. 2 reviewers assessed and selected
the RCTs by means of the Jadad questionnaire and ex-
tracted data. We will contact the author to obtain the
incomplete data.
Statistical analysis
Statistical analyses were performed with Rev Man 4.2
(the Cochrane Library). Results were expressed as
weighed mean difference (WMD) for continuous vari-
ables and 95% confidence interval (CI) for odds ratio
(OR). As to trials with a considerable degree of hetero-
geneity, fixed effects model will be used, otherwise, ran-
dom effects model will be used. Funnel plot analysis
will be used to analyze the bias.
RESULTS
Process for eligibility of randomized controlled trials
Two hundred and forty articles were obtained. The ti-
tle and abstract of each article were evaluated and full
texts of 46 articles were further evaluated. Among 37
excluded studies, 15 studies were not involved in liver
Yang hyperactivity syndrome, 13 studies were self con-
trolled study, 1 study was not randomized, 2 studies'
data were not complete, and 6 studies were duplicate
publications. Total 9 studies involving 784 patients
were enrolled in statistical analysis.
Characteristics of studies
Studies' characteristics are summarized in Table 1.
Quality assessment
Study Quality is evaluated with Jadad Questionnaire:
Whether is the method of randomization described in
the paper? Whether is the method appropriate? Wheth-
er is the method of blinding described? Whether is it
appropriate? Whether are withdrawals and dropouts de-
scribed? Only 3 studies describe the method of ran-
domization. All studies don't describe allocation con-
cealment and blinding. Only 1 study involves with-
drawal and its reason. The quality assessments of the
studies are summarized in Table 2.
Meta-analysis
All the studies describe blood pressure as outcome mea-
sure and 3 studies describe SOD as outcome measure.
We compared the changes in blood pressure and SOD
before and after treatment between the 2 groups and
conducted the Meta analysis.
Decreasing BP effect
Heterogeneity test showed that the studies on diastolic
pressure had a considerable degree of heterogeneity (P=
0.008<0.05), random effects model was used in the sta-
tistical analysis, the studies on systolic pressure had
good homogeneity (P=0.34>0.05), and fixed effects
model was used in the statistical analysis. Although BP
decrease in the treatment group was larger than that in
the control group after treatment, the Meta analysis
showed that the statistical difference between the 2
groups was not significant. Diastolic blood pressure (P=
0.10) and systolic blood pressure (P=0.34).
Increasing SOD effect
Heterogeneity test showed that the studies on SOD
had good homogeneity (P=0.10>0.05) and fix effects
model was used in the statistical analysis. Meta analysis
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showed that the statistical difference between the 2
groups was significant (P=0.01) and the treatment
group showed better effect.
Publication bias
We created funnel plots to test our review for publica-
tion bias and the funnel plots showed skew distribu-
tion. In this analysis, funnel plots showed that a publi-
cation bias cannot be excluded.
DISCUSSION
Hypertension, a common disease, is a main risk factor
for cardiocerebro vascular diseases. At present, 200 mil-
lion hypertension patients in China, accounting for al-
most 1/5 of the hypertension patients in the world,11
excessively consume medical and social resources,
bringing a heavy burden to the family and the state.
Therefore, it is critical to find effective antihyperten-
sive medications. Traditional Chinese medicine plays
an important role in treating hypertension.
In TCM theory, liver Yang hyperactivity is the main
cause for hypertension, and calming the liver wind and
liver Yang is an important treatment method. Tianma-
gouteng decoction, a traditional formula consisting of
11 herbs, such as Tianma (Gastrodia elata Blume),
Gouteng (Gambir Plant), Shijueming (Concha Hali-
otidis), Duzhong (Eucommia Ulmoides), Niuxi (Achy-
ranthes Bidentata) and Sangjisheng (Taxillus Chinensis),
can calm the liver wind and liver Yang and is common-
ly used to treat hypertension.
We performed Meta analysis to get better insight into
the effectiveness of Tianmagouteng decoction for the
treatment of primary hypertension with liver Yang hy-
peractivity syndrome. However, we have found that
most involved studies are poor in quality according to
Jadad score method. For example, most studies don't
describe the method of randomization. Therefore,
whether these studies are randomized is unknown. All
studies don't mention the allocation concealment and
blinding, causing performance bias and detection bias.
Therefore, the results based on these studies are less
Study
Gong YP 20032
Tan HY 20033
Liu WP 20044
Xing ZH 20045
Cai CL 20056
Wu ZC 20087
Yu Y 20108
Chu ZC 20119
Zhang C 201110
Patients (n)
Treatment Control
30
30
30
60
60
60
30
60
37
30
30
30
58
52
60
30
60
37
Tianmagouteng Yin
Tianmagouteng Yin
Tianmagouteng Yin
Tianmagouteng Yin
Tianmagouteng Yin
Tianmagouteng Yin
Tianmagouteng Yin
Tianmagouteng Yin
Tianmagouteng Yin
Intervention
Treatment Control
Captopril
Felodipine
Nitrendipine
Nitrendipine
Nitrendipine
Nifedipine
Nifedipine
Benazepril
Captopril
Duration
4 weeks
4 weeks
4 weeks
4 weeks
4 weeks
4 weeks
4 weeks
4 weeks
4 weeks
BP, TCM symptoms
BP, GSH-PX
BP, SOD
BP, Life Quality
BP, SOD, MDA
BP, TCM symptoms
BP, SOD, ET
BP, Life Quality
BP, NO
Outcome
Table 1 Characteristics of included RCTs
Notes: RCTs: randomized controlled trials; BP: blood pressure; TCM: Traditional Chinese Medicine; GSH-PX: Glutathione Peroxidase;
SOD: Superoxide Dismutase; MDA: Malondialdehyde; ET: Endothelin; NO: Nitric Oxide.
Table 2 Quality assessment of Included randomized controlled trials
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Study
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Method of randomization
Unclear
Unclear
Unclear
Random number table
Unclear
Unclear
Unclear
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Lot
Allocation concealment
Unclear
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Unclear
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Unclear
Unclear
Unclear
Unclear
Unclear
Blinding
Unclear
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Unclear
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Unclear
Single blind
Withdrawals
and dropouts
Unclear
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Unclear
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No
Unclear
Unclear
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Jadad
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1
1
1
2
2
1
1
1
2
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convincing.
The result shows that it is feasible to apply Tianma-
gouteng decoction in the treatment of hypertension
with liver Yang hyperactivity syndrome, and its effect is
similar to that of western medicine. It is reported that
patients with hypertension showed increased oxidative
stress and decreased anti-oxidative ability, resulting in
vascular endothelial injury and inflammatory reaction
to promote the progression of atherosclerosis (AS).12
SOD, the most important antioxidant enzyme, can
clear oxygen free radical and slow AS. Our study shows
that as compared with western medicine, Tianma-
gouteng decoction can significantly increase the SOD
level in hypertension patients, thus improving the oxi-
dative stress status in hypertension patients.
In our study, due to small samples, the clinical hetero-
geneity in all the enrolled studies influences the result
and conclusion of the Meta analysis. As shown in the
funnel plot, the publication bias in the study also influ-
ences the objectivity of the evaluation. Because only 3
articles describe TCM symptoms and life quality,
the effect of Tianmagouteng decoction on TCM
symptoms and life quality cannot be evaluated. All
studies don't describe side effects, dropouts or with-
drawals. Therefore, due to poor quality of enrolled
studies, the effectiveness of Tianmagouteng decoc-
tion for the treatment of primary hypertension
with liver Yang hyperactivity syndrome needs to be
further studied.
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